Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study 3 November 2021 | By Anna Begley (Drug Target Review) The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Researchers identify COVID-19 proteins that cause blood vessel damage 3 November 2021 | By Anna Begley (Drug Target Review) Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Moderna and Metagenomi to develop in vivo gene therapies 3 November 2021 | By Anna Begley (Drug Target Review) Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
Label-free technique could revolutionise tissue analyses 2 November 2021 | By Anna Begley (Drug Target Review) A new high-resolution virtual microscopy technique enables the rapid visualisation of tissue, paving the way for histopathology analysis during surgery.
Monoclonal antibodies prevent COVID-19 inflammation in macaques 2 November 2021 | By Anna Begley (Drug Target Review) Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
Pathway and enzyme responsible for CKD thrombosis identified 2 November 2021 | By Anna Begley (Drug Target Review) Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
GLP-1 and GIP receptor agonists reduce mouse obesity in pre-clinical study 1 November 2021 | By Anna Begley (Drug Target Review) Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Scientists eliminate key Alzheimer’s feature in animal model 1 November 2021 | By Anna Begley (Drug Target Review) Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
NMR method could uncover details of cancer and neurodegeneration development 1 November 2021 | By Anna Begley (Drug Target Review) Scientists have used nuclear magnetic resonance (NMR) spectroscopy to investigate the protein p53, which they say could advance cancer studies.
$9 million grant awarded to uncover whether Parkinson’s starts in the nose 29 October 2021 | By Anna Begley (Drug Target Review) A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
Machine learning models predict antibiotic resistance spread 29 October 2021 | By Anna Begley (Drug Target Review) Scientists have used several machine learning models to predict bacterial gene exchange, which could reveal novel antibiotic targets.
Novel label-free exosome profiling method shows success at detecting cancer 29 October 2021 | By Victoria Rees (Drug Target Review) A new label-free technique has been developed for molecularly specific exosome biosensing in diagnostics and biomarker detection.
Albert Einstein researcher receives NIC award to study two blood cancers 28 October 2021 | By Anna Begley (Drug Target Review) Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Scientists target ALS and dementia RNA using novel molecule 28 October 2021 | By Anna Begley (Drug Target Review) The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Raman spectroscopy used to determine immunotherapy effectiveness 28 October 2021 | By Anna Begley (Drug Target Review) Researchers used Raman spectroscopy to monitor immunotherapy response in mice, potentially improving cancer treatments in the future.
